Oncology PracticePFS better with first-line pazopanib vs. sorafenib in mRCCOctober 16, 2017Renal Cell Carcinoma
Oncology PracticeCheckmate 214: Upfront nivo/ipi bests TKI in advanced RCCSeptember 28, 2017Renal Cell CarcinomaImmunotherapyImmuno-oncology
Oncology PracticeFDA approves biosimilar to bevacizumabSeptember 14, 2017GastroenterologyLung CancerGynecologic CancerCNS/Brain CancerRenal Cell CarcinomaNeuro-oncologyGI Oncology
Oncology PracticePROTECT trial: No DFS benefit with adjuvant pazopanib for high-risk RCCSeptember 14, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticePembrolizumab, nivolumab linked to 3% rate of neurologic eventsSeptember 5, 2017Immuno-oncologyPatient & Survivor CareHodgkin LymphomaMelanomaLung CancerRenal Cell CarcinomaHead & Neck/Thyroid Cancers
Oncology PracticeTivozanib gets EU approval for advanced RCCAugust 30, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeAdverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic reviewAugust 28, 2017Immuno-oncologyImmunotherapyMelanomaRenal Cell CarcinomaLung Cancer
Oncology PracticeExelixis seeks expanded indication for cabozantinib in RCCAugust 18, 2017Renal Cell Carcinoma
Oncology PracticeFDA advisory committee to consider adjuvant sunitinib for RCCAugust 16, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeSequential pazopanib and everolimus nets good survival in metastatic RCCAugust 8, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeNo survival benefit with adjuvant girentuximab in high-risk RCCJuly 19, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeSavolitinib improves PFS in some with MET-driven papillary renal cell carcinomaJuly 6, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticePROTECT: Pazopanib falls short as adjuvant therapy for high-risk RCCJune 19, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeImmune-agonist combo has activity against several tumor typesJune 5, 2017Immuno-oncologyImmunotherapyBreast CancerMelanomaRenal Cell CarcinomaGynecologic CancerGenitourinary Cancer
Oncology PracticeAlternating therapy in renal cell carcinoma fails to show an advantageMay 17, 2017Renal Cell CarcinomaGenitourinary Cancer
